AKT1 and breast cancer: Studies like the STIC-CTC and DETECT-III trials emphasize the predictive value of CTC quantity and characteristics [4–6] and genomic analysis of CTCs has revealed mutations in genes such as AKT1 and PIK3CA, crucial for targeted breast cancer treatments [9–11].